PRO 118

Drug Profile

PRO 118

Alternative Names: PRO-118

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Laboratorios Sophia
  • Class Antihistamines; Eye disorder therapies
  • Mechanism of Action Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic conjunctivitis

Most Recent Events

  • 03 Jun 2013 Laboratorios Sophia suspends a phase II trial in Allergic conjunctivitis in Mexico (NCT01541904)
  • 03 Jun 2013 Laboratorios Sophia suspends a phase III trial in Allergic conjunctivitis in Mexico (NCT01657240)
  • 30 Nov 2012 Phase-III clinical trials in Allergic conjunctivitis in Mexico (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top